Morgan Kruse

Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US

Anju Parthan, Morgan Kruse, Nicole Yurgin et al. · Applied Health Economics and Health Policy · 2013 · 80 citations

Pharmacy, Pharmacoeconomics, Bone Metabolism +15

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

Stuart L. Silverman, Irene Agodoa, Morgan Kruse et al. · Journal of Osteoporosis · 2015 · 34 citations · Full text

Pharmacy, Geriatric Medicine, Pharmacoeconomics +17

Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States

Martin S. Tallman, Francesco Lo‐Coco, Gisoo Barnes et al. · Clinical Lymphoma Myeloma & Leukemia · 2015 · 23 citations

Pharmacy, Hematology, Pharmacoeconomics +17

A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture

Claire E O’Hanlon, Anju Parthan, Morgan Kruse et al. · Clinical Therapeutics · 2017 · 21 citations · Full text

Medicine, Pharmacoeconomics, Bone Metabolism +16

Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States

Michelle Vu, Amy Duhig, Abhishek Tibrewal et al. · Journal of Managed Care & Specialty Pharmacy · 2023 · 12 citations · Full text

Medicine, Child Health, Pediatrics +13